Quick Answer
Renalytix plc reported Cash and Equivalents of $4.68 million for fiscal year 2024.
Renalytix plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $4.68M | -81.0% |
| 2023 | $24.68M | -40.3% |
| 2022 | $41.33M | -36.5% |
| 2021 | $65.13M | +389.9% |
| 2020 | $13.29M | +62.1% |
| 2019 | $8.20M | +9901.2% |
| 2018 | $82.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $909.0K | -93.5% | -80.6% |
| June 30, 2024 | $4.68M | -81.0% | -0.5% |
| March 31, 2024 | $4.70M | — | -16.3% |
| December 31, 2023 | $5.62M | — | -59.5% |
| September 30, 2023 | $13.89M | — | -43.7% |
| June 30, 2023 | $24.68M | — | — |
- Renalytix plc showed a decrease of -81.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2024 period, Renalytix plc’s cash and equivalents has grown by 5607.3% (from $82.0 thousand to $4.68 million).
- The most recent figure is from Renalytix plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on September 30, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: